Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study to Compare 3 Lots of NVX-CoV2373 in Adults
NCT05463068Phase 3Completed
- Sponsor
- Novavax
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started Jul 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05463068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463068.